The Technical Analyst
Lexicon Pharmaceuticals [LXRX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Lexicon Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
1.23% $1.650
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 406.29 mill |
| EPS: | -0.800 |
| P/E: | -2.06 |
| Earnings Date: | Apr 30, 2024 |
| SharesOutstanding: | 246.24 mill |
| Avg Daily Volume: | 4.88 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.06 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.35x |
| Company: PE -2.06 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.391 (-123.70%) $-2.04 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.416 - 1.904 ( +/- 14.70%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-13 | Artal International S.c.a. | Buy | 1 150 922 | Series A Convertible Preferred Stock |
| 2024-02-28 | Alexander Kristen | Buy | 15 927 | Common Stock |
| 2024-02-28 | Alexander Kristen | Sell | 11 793 | Common Stock |
| 2024-02-28 | Alexander Kristen | Buy | 10 616 | Common Stock |
| 2024-02-28 | Alexander Kristen | Buy | 2 700 | Common Stock |
| INSIDER POWER |
|---|
| 92.62 |
| Last 98 transactions |
| Buy: 35 947 123 | Sell: 970 903 |
Forecast:
16:00 - $1.660
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.660
Forecast 2: 16:00 - $1.660
Forecast 3: 16:00 - $1.660
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.650 (1.23% ) |
| Volume | 2.97 mill |
| Avg. Vol. | 4.88 mill |
| % of Avg. Vol | 60.86 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LXRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $2.32 | N/A | Active |
|---|
LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Latest Press Releases
2024-04-18 08:00:00 - Press Release
Lexicon Pharmaceuticals To Host 2024 Investor Day
Includes business and scientific updates from lexicon executives and leading medical experts in hypertrophic cardiomyopathy, type 1 diabetes and diabetic peripheral neuropathic pain includes business and scientific updates from lexicon executives and leading medical experts in hypertrophic cardiomyopathy, type 1 diabetes and diabetic peripheral neuropathic pain
2024-03-25 09:20:00 - Press Release
Clinical Data On The Impact Of Sotagliflozin On Stroke And Heart Attack Risk Among Four Lexicon-sponsored Presentations At The American College Of Cardiology 73rd Annual Scientific Session & Expo
The woodlands, texas, march 25, 2024 (globe newswire) -- lexicon pharmaceuticals, inc. (nasdaq: lxrx) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport proteins (sglt2 and sglt1), will be delivered during the american college of cardiology 73rd annual scientific session & expo being held april 6 - 8, 2024 in atlanta, georgia, including results from a post-hoc evaluation of the efficacy of sotagliflozin in reducing stroke events in patients with type 2 diabetes, chronic kidney disease (ckd), and high cardiovascular (cv) risk in the scored phase 3 clinical trial.
2024-03-11 07:15:00 - Press Release
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 financial Results And Provides Business Update
Commercial launch of inpefa ® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access
2024-03-11 07:05:00 - Press Release
Lexicon Announces Oversubscribed $250 Million Private Placement Of Equity Securities
The woodlands, texas, march 11, 2024 (globe newswire) -- lexicon pharmaceuticals, inc. (nasdaq: lxrx) (“ lexicon ”) today announced it has entered into a securities purchase agreement (the “purchase agreement”) for a private investment in public equity financing that is expected to result in gross proceeds of approximately $250 million, before deducting placement agent fees and offering expenses. pursuant to the terms of the purchase agreement, lexicon will sell approximately 2.3 million shares of series a convertible preferred stock (the “series a convertible preferred stock”), at a price per share of $108.50, convertible into approximately 115.2 million shares of its common stock, par value $0...
2023-12-21 16:15:00 - Press Release
Lexicon Pharmaceuticals To Participate In The 42nd Annual Jpmorgan Healthcare Conference
The woodlands, texas, dec. 21, 2023 (globe newswire) -- lexicon pharmaceuticals, inc. (nasdaq: lxrx) today announced its participation in the 42nd annual jpmorgan healthcare conference taking place january 8 – january 12, 2024.
Latest News
2024-04-16 13:01:16 - Zacks Investment Research
All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy
Lexicon (LXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-13 13:46:08 - Zacks Investment Research
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
New post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.
2024-03-11 09:26:04 - Zacks Investment Research
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.16 per share a year ago.
2024-02-29 11:01:17 - Zacks Investment Research
Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2023-11-03 09:00:00 - GlobeNewsWire
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023
THE WOODLANDS, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2023 financial results on Wednesday, November 8th, 2023 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss the financial results and to provide a business update.
2023-10-16 10:35:20 - PennyStocks
3 Top Penny Stocks to Buy According To Insiders In October
Penny stocks, defined as stocks trading under $5 per share, offer traders huge upside potential but also carry significant risks. One strategy used by some investors to identify promising penny stocks is tracking insider trading activity through SEC filings.
2023-10-11 12:47:38 - Zacks Investment Research
Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts
A pharmacy benefit manager decides to place Lexicon's (LXRX) heart failure drug as a preferred product on Medicare national formularies on Nov. 1. The stock jumped 12% post this announcement.
2023-10-10 11:25:34 - The Motley Fool
Why Shares of Lexicon Pharmaceuticals Are Up Tuesday
Lexicon just launched heart failure therapy Inpefa this year. The drug was approved by the FDA in May.
2023-10-10 07:47:59 - Proactive Investors
Lexicon Pharmaceuticals shares rise on Express Scripts support for Inpefa heart drug
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares jumped 9% in Tuesday pre-market trading after it announced that its Inpefa heart failure drug has been supported for Medicare patients by Express Scripts from November 1. The company's stock declined 7% on Monday.
2023-09-28 09:00:00 - GlobeNewsWire
Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023
